US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 9322037B2
· Liu et al.
· 2016
[cited by applicant]
US 9512446B1
· Joung et al.
· 2016
[cited by applicant]
US 9752132B2
· Joung et al.
· 2017
[cited by applicant]
US 9926546B2
· Joung et al.
· 2018
[cited by applicant]
US 20100076057A1
· Sontheimer et al.
· 2010
[cited by applicant]
US 20140170753A1
· Zhang
· 2014
[cited by applicant]
US 20140179770A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186843A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140186919A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140189896A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140199767A1
· Barrangou et al.
· 2014
[cited by applicant]
US 20140201857A1
· Fahrenkrug et al.
· 2014
[cited by applicant]
US 20140212869A1
· Sampas et al.
· 2014
[cited by applicant]
US 20140242664A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140242699A1
· Zhang
· 2014
[cited by applicant]
US 20140273230A1
· Chen et al.
· 2014
[cited by applicant]
US 20140294773A1
· Brouns et al.
· 2014
[cited by applicant]
US 20140309487A1
· Lee et al.
· 2014
[cited by applicant]
US 20140310828A1
· Lee et al.
· 2014
[cited by applicant]
US 20140310830A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140315985A1
· May et al.
· 2014
[cited by applicant]
US 20140335620A1
· Zhang et al.
· 2014
[cited by applicant]
US 20140349400A1
· Jakimo et al.
· 2014
[cited by applicant]
US 20140357530A1
· Zhang et al.
· 2014
[cited by applicant]
US 20150031134A1
· Zhang et al.
· 2015
[cited by applicant]
US 20150050699A1
· Siksnys et al.
· 2015
[cited by applicant]
US 20190177710A1
· Lee
· 2019
[cited by applicant]
US 20200140835A1
· Joung et al.
· 2020
[cited by applicant]
US 20210355465A1
· Joung et al.
· 2021
[cited by applicant]
US 20210380955A1
· Bryson
· 2021
[cited by examiner]
CA 3069296
· 2019
[cited by applicant]
CN 104854241
· 2015
[cited by applicant]
CN 105543195
· 2016
[cited by applicant]
CN 106062197
· 2016
[cited by applicant]
WO WO2008108989
· 2008
[cited by applicant]
WO WO2010054108
· 2010
[cited by applicant]
WO WO2012164565
· 2012
[cited by applicant]
WO WO2013098244
· 2013
[cited by applicant]
WO WO2013176772
· 2013
[cited by applicant]
WO WO2013176772A1
· 2013
[cited by examiner]
WO WO2014124284
· 2014
[cited by applicant]
WO WO2014144288
· 2014
[cited by applicant]
WO WO2014144592
· 2014
[cited by applicant]
WO WO2014152432
· 2014
[cited by applicant]
WO WO2014152432A2
· 2014
[cited by examiner]
WO WO2014191521
· 2014
[cited by applicant]
WO WO2014204724
· 2014
[cited by applicant]
WO WO2014204725
· 2014
[cited by applicant]
WO WO2015089364
· 2015
[cited by applicant]
WO WO2015089486
· 2015
[cited by applicant]
WO WO2015200378
· 2015
[cited by applicant]
WO WO2016115179
· 2016
[cited by applicant]
WO WO2016115355
· 2016
[cited by applicant]
WO WO2016141224
· 2016
[cited by applicant]
WO WO2016205613
· 2016
[cited by applicant]
WO WO2017015015
· 2017
[cited by applicant]
WO WO2017040348
· 2017
[cited by applicant]
WO WO2017070633
· 2017
[cited by applicant]
WO WO2017070633A2
· 2017
[cited by examiner]
WO WO2017081288
· 2017
[cited by applicant]
WO WO2017184768
· 2017
[cited by applicant]
WO WO2018119359
· 2018
[cited by applicant]
WO WO2019009682
· 2019
[cited by applicant]
WO WO2019040650
· 2019
[cited by applicant]
WO WO2019079347
· 2019
[cited by applicant]
WO WO2019092042
· 2019
[cited by applicant]
WO WO2019217941
· 2019
[cited by applicant]
WO WO2019217942
· 2019
[cited by applicant]
WO WO2019217943
· 2019
[cited by applicant]
WO WO2019217944
· 2019
[cited by applicant]
WO WO2020041751
· 2020
[cited by applicant]
WO WO2021042047
· 2021
[cited by applicant]
International Preliminary Report on Patentability in International Appln. No. PCT/US2021/014900, mailed on Aug. 4, 2022, 8 pages.
[cited by applicant]
Kleinstiver et al., “Supplementary Materials: Engineered CRISPR-Cas9 nucleases with altered PAM specificities,” Nature, Jul. 2015, 523(7561):481-497, 289 pages.
[cited by applicant]
U.S. Appl. No. 61/652,086, filed May 25, 212, Jinek et al.
[cited by applicant]
Abudayyeh et al., “A Cytosine Deaminase for Programmable Single-base RNA Editing,” Science, Jul. 26, 2019, 365(6451):382-386.
[cited by applicant]
Al-Attar et al, “Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs): The Hallmark of an Ingenious Antiviral Defense Mechanism in Prokaryotes,” Biol Chem. 2011, 392(4):277-289.
[cited by applicant]
Anders et al., “4un3: Crystal structure of Cas9 bound to PAM-containing DNA target,” RCSB Protein Data Bank, May 25, 2014, retrieved on May 6, 2016, retrieved from URL <http://www.rcsb.org/pdb/explore/explore.do?structu…
[cited by applicant]
Anders et al., “Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease,” Nature, 2014, 513:569-573.
[cited by applicant]
Anders et al., “Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9,” Molecular Cell, Mar. 17, 2016, 61(6):895-902.
[cited by applicant]
Balemans et al., “Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST),” Hum Mol Genet., 2001, 10(5):537-543.
[cited by applicant]
Barrangou & May, “Unraveling the potential of CRISPR-Cas9 for gene therapy,” Expert Opin. Biol. Ther., 2014, 15:311-314.
[cited by applicant]
Bisaria et al., “Lessons from Enzyme Kinetics Reveal Specificity Principles for RNA-Guided Nucleases in RNA Interference and CRISPR-Based Genome Editing,” Cell Syst., Jan. 2017, 4(1):21-29.
[cited by applicant]
Canela et al., “DNA Breaks and End Resection Measured Genomewide by End Sequencing,” Molecular Cell, 2016, 63: 1-14.
[cited by applicant]
Canver et al., “BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis,” Nature., 2015, 527(7577), 192-7.
[cited by applicant]
Carroll, “A CRISPR Approach to Gene Targeting,” Molecular Therapy, Sep. 2012, 20:(9)1658-1660.
[cited by applicant]
Casini et al, “A highly specific SpCas9 variant is identified by in vivo screening in yeast,” Nat. Biotechnol., 2018, 36(3):265-271.
[cited by applicant]
Cencic et al., “Protospacer Adjacent Motif (PAM)-Distal Sequences Engage CRISPR Cas9 DNA Target Cleavage,” Oct. 2014, PLOS One, 9(10):e109213, 13 pages.
[cited by applicant]
Chen & Zhao, “A highly sensitive selection method for directed evolution of homing endonucleases,” Nucleic Acids Res., 2005, 33(18):e154, 7 pages.
[cited by applicant]
Chen et al., “Enhanced proofreading governs CRISPR-Cas9 targeting accuracy,” Nature, Oct. 2017, 550(7676):407-410.
[cited by applicant]
Choi & Meyerson, “Targeted genomic rearrangements using CRISPR/Cas technology,” Nat Commun., Apr. 24, 2014, 5:3728, 9 pages.
[cited by applicant]
Chu et al., “Rationally Designed Base Editors for Precise Editing of the Sickle Cell Disease Mutation,” The CRISPR Journal, Apr. 20, 2021, 4(2):169-177.
[cited by applicant]
Chylinski et al., “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems,” RNA Biol., May 2013, 10:726-737.
[cited by applicant]
Clement et al., “CRISPResso2 provides accurate and rapid genome editing sequence analysis,” Nature Biotechnology, Feb. 2019, 37:224-226.
[cited by applicant]
Cong et al., “Multiplex genome engineering using CRISPR/Cas systems,” Science, 2013, 339:819-823 (Author Manuscript).
[cited by applicant]
Courtney et al., “CRISPR/Cas9 DNA cleavage at SNP-derived PAM enables both in vitro and in vivo KRT12 mutation-specific targeting,” Gene Ther., 2016, 23(1):108-12.
[cited by applicant]
Cox et al., “Congenital insensitivity to pain: novel SCN9A missense and in-frame deletion mutations,” Hum Mutat., 2010, 31:E1670-86.
[cited by applicant]
Crosetto et al, “Nucleotide-resolution DNA double-strand break mapping by next-generation sequencing,” Apr. 2013, Nat Methods 10(4): 361-365.
[cited by applicant]
Dagdas et al., “A Conformational Checkpoint Between DNA Binding and Cleavage by CRISPR-Cas9,” Science Advances, Aug. 2017, 3(8): eaao0027.
[cited by applicant]
Deltcheva et al., “CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III,” Nature, 2011, 471(7340):602-607 (Author Manuscript).
[cited by applicant]
Deveau et al., “Phage response to CRISPR-encoded resistance in
[cited by applicant]
DiCarlo et al., “Genome engineering in
[cited by applicant]
Ding et al., “Enhanced efficiency of human pluripotent stem cell genome editing through replacing TALENs with CRISPRs,” Cell Stem Cell., Apr. 4, 2013, 12(4):393-4 (Author Manuscript).
[cited by applicant]
Doench et al., “Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9,” Nature Biotechnology, Jan. 18, 2016, 34:184-191, 12 pages.
[cited by applicant]
Dong et al., “The crystal structure of Cpf1 in complex with CRISPR RNA,” Nature, 2016, 532(7600):522-526.
[cited by applicant]
Doudna & Charpentier, “The new frontier of genome engineering with CRISPR-Cas9,” Science, Nov. 2014, 346(6213):1258096, 10 pages.
[cited by applicant]
Doyon et al., “Directed evolution and substrate specificity profile of homing endonuclease I-SceI,” J. Am. Chem. Soc., 2006, 128:2477-2484.
[cited by applicant]
Duan et al., “Genome-wide identification of CRISPR/Cas9 off-targets in human genome,” Cell Res, 2014, 24(8):1009-1012.
[cited by applicant]
Elliott et al., “Gene Conversion Tracts from Double-Strand Break Repair in Mammalian Cells,” Mol Cell Biol., 1998, 18:93-101.
[cited by applicant]
Esvelt et al., “Orthogonal Cas9 proteins for RNA-guided gene regulation and editing,” Nat. Methods, 2013, 10:1116-1121.
[cited by applicant]
Findlay et al., “Saturation editing of genomic regions by multiplex homology-directed repair,” Nature, 2014, 513:120-3.
[cited by applicant]
Flannick et al., “Loss-of-function mutations in SLC30A8 protect against type 2 diabetes,” Nat Genet., 2014, 46:357-63.
[cited by applicant]
Fonfara et al., “Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systems.” Nucleic Acids Res., 2014, 42(4): 2577-2590.
[cited by applicant]
Fu et al., “High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells,” Nat Biotechnol., 2013, 31:822-826 (Author Manuscript).
[cited by applicant]
Fu et al., “Improving CRISPR-Cas nuclease specificity using truncated guide RNAs,” Nat. Biotechnol, Mar. 2014, 32(3):279-284.
[cited by applicant]
Gabriel et al., “An unbiased genome-wide analysis of zinc-finger nuclease specificity,” Nat Biotechnol., 2011, 29:816-823.
[cited by applicant]
Gagnon et al, “Efficient mutagenesis by Cas9 protein-mediated oligonucleotide insertion and large-scale assessment of single-guide RNAs,” PLoS One, 2014, 9, e98186.
[cited by applicant]
Gaj et al., “ZFN, TALEN and CRISPR/Cas-based methods for genome engineering,” Trends Biotechnol,, Jul. 2013, 31(7):397-405.
[cited by applicant]
Gao et al., “Engineered Cpf1 variants with altered PAM specificities,” Nat Biotechnol., 2017, 35:789-792.
[cited by applicant]
Gasiunas et al., “Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria,” Proc Natl Acad Sci USA, 2012, 109(39):E2579-E2586.
[cited by applicant]
Gaudelli et al., “Programmable base editing of A⋅T to G⋅C in genomic DNA without DNA cleavage,” Nature, Nov. 23, 2017, 551:464-471.
[cited by applicant]
Gehrke et al., “An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities,” Nature Biotechnology, Nov. 2018, 36(10):977-982, 8 pages.
[cited by applicant]
GenBank Accession No. AKS40380.1, “Cas9 [Synthetic plasmid pFC330],” Aug. 2, 2015, 1 page.
[cited by applicant]
GenBank Accession No. EOS46485.1, “The Genome Sequence of Lachnospiraceae bacterium COE1,” May 29, 2013, 2 pages.
[cited by applicant]
GenBank Accession No. NP_472073, “hypothetical protein lin2744 [listeria innocua C!ip11262],” Dec. 17, 2014, 2 pages.
[cited by applicant]
GenBank Accession No. WP_010922251.1, “type II CR.ISPR RNA-guided endonuclease Cas9 [
[cited by applicant]
Grünewald et al., “CRISPR DNA Base Editors with Reduced RNA Off-Target and Self-Editing Activities,” Nature Biotechnology, Sep. 2, 2019, 37(9):1041-1048, 10 pages.
[cited by applicant]
Grünewald et al., “Transcriptome-wide off-target RNA editing induced by CRISPR-guided DNA base editors,” Nature, May 16, 2019, 569(7756):433-437, 18 pages.
[cited by applicant]
Guilinger et al., “Fusion of Catalytically Inactive Cas9 to FokI Nuclease Improves the Specificity of Genome Modification,” Nat Biotechnol., Apr. 2014, 32:577-582.
[cited by applicant]
Guo et al., “Structural insights into a high fidelity variant of SpCas9,” Cell Res., 2019, 29:183-192.
[cited by applicant]
Hale et al, “Essential Features and Rational Design of CRISPR RNAs That Function With the Cas RAMP Module Complex to Cleave RNAs,” Mol Cell., Feb. 2012, 45(3):292-302.
[cited by applicant]
Harper et al., “Protective alleles and modifier variants in human health and disease,” Nat Rev Genetics, 2015, 16:689-701.
[cited by applicant]
Heigwer et al., “E-CRISP: fast CRISPR target site identification,” Nat Methods, Feb. 2014, 11:122-123.
[cited by applicant]
Heler et al., “Cas9 specifies functional viral targets during CRISPR-Cas adaptation,” Nature, 2015, 519:199-202.
[cited by applicant]
Hirano et al., “Structural Basis for the Altered PAM Specificities of Engineered CRISPR-Cas9,” Mol Cell, Mar. 2017, 61:886-94.
[cited by applicant]
Horvath et al., “Diversity, activity, and evolution of CRISPR loci in
[cited by applicant]
Hou et al, “Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis,” Proc. Natl. Acad. Sci. USA, Sep. 2013, 110(39):15644-15649.
[cited by applicant]
Hsu et al., “Development and Applications of CRISPR-Cas9 for Genome Engineering,” Cell, 2014, 157(6):1262-1278.
[cited by applicant]
Hsu et al., “DNA targeting specificity of RNA-guided Cas9 nucleases,” Nat Biotechnol., 2013, 31:827-832.
[cited by applicant]
Hu et al., “Evolved Cas9 variants with broad PAM compatibility and high DNA specificity,” Nature, 2018, 556:57-63.
[cited by applicant]
Hwang et al., “Efficient In Vivo Genome Editing Using RNA-Guided Nucleases,” Nat Biotechnol., 2013, 31:227-229 (Author Manuscript).
[cited by applicant]
Iyer et al., “Prediction of novel families of enzymes involved in oxidative and other complex modifications of bases in nucleic acids,” Cell Cycle, 2009, 8(11):1698-710.
[cited by applicant]
Jiang et al., “A Cas9-guide RNA complex preorganized for target DNA recognition,” Science, Jun. 2015, 348(6242):1477-1481.
[cited by applicant]
Jiang et al., “CRISPR-assisted editing of bacterial genomes,” Nat Biotechnol., 2013, 31:233-239 (Author Manuscript).
[cited by applicant]
Jiang et al., “Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage,” Science, Feb. 2016, 351(6275):867-871.
[cited by applicant]
Jinek et al., “A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity,” Science, 2012, 337:816-821.
[cited by applicant]
Jinek et al., “RNA-programmed genome editing in human cells,” Elife, 2013, 2:e00471, 9 pages.
[cited by applicant]
Jinek et al., “Structures of Cas9 endonucleases reveal RNA-mediated conformational activation,” Science, Mar. 2014, 343(6176):1247997, 13 pages.
[cited by applicant]
Kan et al., “Mechanisms of precise genome editing using oligonucleotide donors,” Genome Res., 2017, 27:1099-1111.
[cited by applicant]
Karvelis et al., “Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements,” Genome Biol., 2015, 16:253, 13 pages.
[cited by applicant]
Keegan et al, “ADAR RNA editing below the backbone,” RNA, Sep. 2017, 23(9):1317-1328.
[cited by applicant]
Kim et al., “Deep learning improves prediction of CRISPR-Cpf1 guide RNA activity,” Nature Biotechnology, Jan. 29, 2018, 36:239-241, 6 pages.
[cited by applicant]
Kim et al., “SpCas9 activity prediction by DeepSpCas9, a deep learning-based model with high generalization performance,” Science Advances, Nov. 6, 2019, 5(11):eaax9249, 9 pages.
[cited by applicant]
Kim et al., “Genome-wide target specificities of CRISPR-Cas9 nucleases revealed by multiplex Digenome-seq,” Genome Res, 2016, 26: 406-415.
[cited by applicant]
Kleinstiver et al., “A unified genetic, computational and experimental framework identifies functionally relevant residues of the homing endonuclease I-BmoI,” Nucleic Acids Res., 2010, 38(7):2411-2427.
[cited by applicant]
Kleinstiver et al., “Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing,” Nat Biotechnol., Feb. 11, 2019, 37:276-282.
[cited by applicant]
Kleinstiver et al., “High-fidelity CRISPR-Cas9 nucleases with No. detectable genome-wide offtarget effects,” Nature, Jan. 2016, 529:490-495.
[cited by applicant]
Kleinstiver et al., “Broadening the targeting range of
[cited by applicant]
Kleinstiver et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities,” Nature, 2015, 523(7561):481-485.
[cited by applicant]
Koblan et al., “Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction,” Nat Biotechnol., Oct. 2018, 36:843-846.
[cited by applicant]
Komor et al, “Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity,” Sci. Adv., Aug. 2017, 3:eaao4774, 9 pages.
[cited by applicant]
Komor et al., “CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes,” Cell, Jan. 12, 2017, 168(1-2):20-36.
[cited by applicant]
Komor et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage,” Nature, May 2016, 533(7603):420-424.
[cited by applicant]
Lin et al., “CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences,” Nucleic Acids Res., 2014, 42:7473-7485.
[cited by applicant]
Lindahl et al., “DNA N-glycosidases: properties of uracil-DNA glycosidase from
[cited by applicant]
Makarova et al., “Evolution and classification of the CRISPR-Cas systems,” Nat. Rev. Microbiol., 2011, 9(6):467-77.
[cited by applicant]
Mali et al., “Cas9 as a versatile tool for engineering biology,” Nature Methods, 2013, 10(10):957-963.
[cited by applicant]
Mali et al., “RNA-guided human genome engineering via Cas9,” Science, Feb. 2013, 339:823-826 (Author Manuscript).
[cited by applicant]
Mali et al., “CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering,” Nat Biotechnol, Sep. 2013, 31(9): 833-838.
[cited by applicant]
McShan et al., “Genome sequence of a nephritogenic and highly transformable M49 strain of
[cited by applicant]
Melamede et al., “Isolation and characterization of endonuclease VIII from
[cited by applicant]
Mojica et al., “Short motif sequences determine the targets of the prokaryotic CRISPR defence system,” Microbiology, Jan. 2009, 155:733-740.
[cited by applicant]
Nishida et al, “Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems,” Science, Sep. 2016, 53(6305), 14 pages.
[cited by applicant]
Nishimasu et al., “Crystal structure of Cas9 in complex with guide RNA and target DNA,” Cell, 2014, 156:935-949.
[cited by applicant]
Nishimasu et al., “Engineered CRISPR-Cas9 nuclease with expanded targeting space,” Science, Sep. 21, 2018, 361(6408):1259-1262.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2016/020756, dated Sep. 14, 2017.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2016/049147, dated Mar. 6, 2018, 8 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/036293, dated Dec. 10, 2019, 8 pages.
[cited by applicant]
PCT International Preliminary Report on Patentability in International Appln. No. PCT/US2018/047577, dated Feb. 25, 2020, 8 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2016/020756, dated Jul. 26, 2016, 12 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2016/049147, dated Dec. 23, 2016, 12 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2017/043753, dated Dec. 28, 2017, 18 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/028919, dated Oct. 1, 2018, 17 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2018/036293, dated Nov. 8, 2018, 13 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/014900, dated Jul. 21, 2021, 12 pages.
[cited by applicant]
PCT International Search Report and Written Opinion in International Appln. No. PCT/US2021/014933, dated Jul. 20, 2021, 12 pages.
[cited by applicant]
PCT Invitation to Pay Additional Fees in International Appln. No. PCT/US2016/049147, dated Oct. 31, 2016, 2 pages.
[cited by applicant]
Perez-Pinera et al., “RNA-guided gene activation by CRISPR-Case9-based transcription factors,” Nat Methods, 2013, 10(10):973-976.
[cited by applicant]
Pinello et al, “Analyzing CRISPR genome-editing experiments with CRISPResso,” Nat. Biotechnol., Jul. 2016, 34(7): 695-697.
[cited by applicant]
Ran et al., “Double Nicking by RNA-Guided CRISPR Cas9 for Enhanced Genome Ediitng Specificity,” Cell, 2013, 154(6):1380-1389.
[cited by applicant]
Ran et al., “In vivo genome editing using
[cited by applicant]
Rees et al., “Base editing: precision chemistry on the genome and transcriptome of living cells,” Nat. Rev. Genet., Dec. 2018, 19(12):770-788.
[cited by applicant]
Reyon et al, “FLASH assembly of TALENs for high-throughput genome editing,” Nat. Biotechnol., May 2012, 30(5):460-465.
[cited by applicant]
Rohland et al., “Cost-effective, high-throughput DNA sequencing libraries for multiplexed target capture,” Genome Research, Jan. 2012, 22:939-946.
[cited by applicant]
Rutkauskas et al., “Directional R-Loop Formation by the CRISPR-Cas Surveillance Complex Cascade Provides Efficient Off-Target Site Rejection,” Cell Rep., Mar. 2015, 10(9):1534-1543.
[cited by applicant]
Sander et al., “CRISPR-Cas systems for editing, regulating and targeting genomes,” Nat Biotechnol., Apr. 2014, 32(4):347-55.
[cited by applicant]
Sang, “Prospects for transgenesis in the chick,” Mechanisms of Development, Sep. 2004, 121:1179-1186.
[cited by applicant]
Sapranauskas et al, “The
[cited by applicant]
Savva et al, “The ADAR protein family,” Genome Biol., Dec. 2012, 13(12):252, 10 pages.
[cited by applicant]
Schuelke et al., “Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child,” New Engl J Med., 2004, 350:2682-2688.
[cited by applicant]
Shah et al, “Protospacer recognition motifs,” RNA Biol., Feb. 2013, 10(5):891-899.
[cited by applicant]
Shi et al., “Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains,” Nat Biotechnol., 2015, 33:661-7.
[cited by applicant]
Slaymaker et al, “Rationally engineered Cas9 nucleases with improved specificity,” Science, Jan. 2016, 351(6268):84-88.
[cited by applicant]
Spencer et al., “Deep mutational scanning of
[cited by applicant]
Sternberg et al., “Conformational control of DNA target cleavage by CRISPR-Cas9” Nature, 2015, 527:110-113.
[cited by applicant]
Sternberg et al., “DNA interrogation by the CRISPR RNA-guided endonuclease Cas9,” Nature, Jan. 2014, 507(7490):62-67.
[cited by applicant]
Suzuki et al., “In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration,” Nature, 2016, 540:144-149.
[cited by applicant]
Szczelkun et al., “Direct observation of R-loop formation by single RNA-guided Cas9 and Cascade effector complexes,” Proc. Natl. Acad. Sci. USA., 111(27):9798-9803.
[cited by applicant]
TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, “Loss-of-function mutations in APOC3, triglycerides, and coronary disease,” New Engl J Med., 2014, 371:22-31.
[cited by applicant]
The Myocardial Infarction Genetics Consortium Investigators, “Inactivating mutations in NPCIL1 and protection from coronary heart disease,” New Engl J Med., 2014, 371:2072-82.
[cited by applicant]
Tsai & Joung., “Defining and improving the genome-wide specificities of CRISPR-Cas9 nucleases,” Nat. Rev. Genet., 2016, 17(5):300-312.
[cited by applicant]
Tsai et al., “Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing,” Nat. Biotechnol., 2014, 32(6):569-576.
[cited by applicant]
Tsai et al., “GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases,” Nat Biotechnol, Feb. 2015, 33:187-197.
[cited by applicant]
UniProt Database Accession No. USULJ7, “Full-Csn1 family CRISPR-associated protein,” Jan. 22, 2014, 1 page.
[cited by applicant]
Vakulskas et al, “A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human haematopoietic stem and progenitor cells,” Nature Medicine, Aug. 2018, 24(8):1216-1224.
[cited by applicant]
Vierstra et al, “Functional footprinting of regulatory DNA,” Nat. Methods, Oct. 2015, 12(10):927-30.
[cited by applicant]
Walton et al., “Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants,” Science, Apr. 17, 2020, 368:290-296, 7 pages.
[cited by applicant]
Wang et al., Regenerative medicine: targeted genome editing in vivo. Cell Research, Jan. 2015, 25: 271-272,.
[cited by applicant]
Wiedenheft et al, “RNA-guided genetic silencing systems in bacteria and archaea,” Nature, 2012, 482:331-338.
[cited by applicant]
Wolf et al, “tadA, an essential tRNA-specific adenosine deaminase from
[cited by applicant]
Wright et al., “Rational design of a split-Cas9 enzyme complex,” Proc. Natl. Acad. Sci. USA., Mar. 2015, 112(10):2984-2989.
[cited by applicant]
Zetsche et al., “Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System,” Cell, 2015, 163:759-771.
[cited by applicant]
Zhang et al., “Comparison of non-canonical PAMS for CRISPR/Cas9-mediated DNA cleavage in human cells,” Sci Rep, Jun. 2014, 4:5405, 5 pages.
[cited by applicant]
Zhang et al., “Processing-Independent CRISPR RNAs Limit Natural Transformation in Neisseria meningitidis,” Mol Cell, May 2013, 50(4):488-503.
[cited by applicant]
Nishimasu et al., “Crystal Structure of
[cited by applicant]
Li et al., “Advances in detecting and reducing off-target effects generated by CRISPR-mediated genome editing,” Journal of Genetics and Genomics, Nov. 2019, 46(11):513-521.
[cited by applicant]
Partial European Search Report in European Appln. No. 21744681.4, dated Dec. 20, 2023, 19 pages.
[cited by applicant]
Lee et al., “Directed evolution of CRISPR-Cas9 to increase its specificity,” Nat Commun., Aug. 2018, 9(1):3048, 10 pages.
[cited by applicant]
Xu et al., “SpRY greatly expands the genome editing scope in rice with highly flexible PAM recognition,” Jan. 2021, 22(1):6, 15 pages.
[cited by applicant]
Nishimasu et al., “Supplemental Information: Crystal Structure of
[cited by applicant]
Extended European Search Report in European Appln. No. 21744681.4, dated Mar. 13, 2024, 17 pages.
[cited by applicant]